CREBBP and neuroendocrine neoplasm: Preclinical studies showed that PRI-724, the second-generation of CBP/catenin antagonist, inhibited cell proliferation and reduced cell growth in a variety of cancer types, including neuroendocrine tumors [48], osteosarcoma [54], head and neck carcinoma [55], hepatocellular carcinoma [56] and also in soft tissue sarcomas [57].